Baptist Heart & Vascular Institute Research
The research department is conducting a heart failure trial with a dual inhibitor SGLT2 and SGLT1. The primary objective is to demonstrate that the study drug reduces cardiovascular mortality and morbidity compared to placebo in hemodynamically stable patients with type 2 diabetes and heart failure. Recent data indicates that sodium-glucose cotransporter 2 inhibitors may reduce heart failure morbidity and mortality in patients with type 2 diabetes. The inhibitors may affect volume status via either or both of the following mechanisms: a sodium and volume reduction and/or a decrease in arterial pressure. There have been no severe hypoglycemia events observed in earlier trials. Eligible subjects must have type 2 diabetes and have been admitted for heart failure.
If you would like further information about our research program, please call 850-484-6690.